Tag:

ImmunoCellular Therapeutics

Latest Headlines

Latest Headlines

ImmunoCellular tanks after cancer vaccine flops on key endpoint in PhII

ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.

Hastings, McGirr to sit on Relypsa board

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

ImmunoCellular taps Andrew Gengos to serve as president

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

UPDATED: Drug developers extol human data in brain cancer fight

A trio of programs in development was highlighted in a Bloomberg article that sheds light on the tricky--and often losing--battle against deadly brain cancer called glioblastoma multiforme.

ImmunoCellular licenses new ovarian cancer target

ImmunoCellular Therapeutics' vaccine, ICT-140, is a cell-based vaccine in early development for the treatment of ovarian cancer.

ImmunoCellular starts Phase II trial of brain cancer vaccine

Wake Forest Baptist Medical Center is heralding its involvement in a new Phase II trial of ImmunoCellular Therapeutics ' ICT-107. The cancer vaccine, which we recently chose as one of 10 promising

ImmunoCellular gains brain cancer vax patent

Los Angeles-based biotech ImmunoCellular Therapeutics has received a patent for its glioblastoma vaccine, ICT-107. The patent, named "System and method for the treatment of cancer, including cancers

Brain cancer vax promising in PhI

A small Phase I trial of an experimental dendritic cell-based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients

Brain cancer vax looks promising in small trial

A small Phase I trial of an experimental dendritic cell based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients